Поражение респираторного тракта при болезни Шёгрена, фокус на интерстициальное заболевание легких

В статье приводится обзор литературы, посвященный современным представлениям о поражении респираторного тракта при болезни Шёгрена (БШ) с акцентом на интерстициальное заболевание легких (ИЗЛ). Обсуждаются также подходы к дифференциальной диагностике, лечению и скринингу БШ-ИЗЛ.

1. Vivino FB, Bunya VY, Massaro-Giordano G, Johr CR, Giattino SL, Schorpion A, et al. Sjogren‘s syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol. 2019;203:81-121. doi: 10.1016/j.clim.2019.04.009

2. Moutsopoulos HM. Sjögren’s syndrome: autoimmune epithelitis. Clin Immunol Immunopathol. 1994;72(2):162-165. doi: 10.1006/clin.1994.1123

3. Сафонова ТН, Васильев ВИ, Лихванцева ВГ. Синдром Шегрена: Руководство для врачей. М.:Издательство Московского государственного университета;2013.

4. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjoegren’s syndrome. A clinical, pathological, and serological study of sixtytwo cases. Medicine (Baltimore). 1965;44:187-231.

5. Свободина ОН, Гуревич ЛА, Васильев ВИ. Клинико-рентгенологическая и дифференциальная диагностика легочных изменений при болезни Шёгрена. Сборник резюме 2-го Всесоюзного конгресса по болезням органов дыхания в Челябинске. М.;1991:175.

6. Свободина ОН, Гуревич ЛА, Васильев ВИ. Клиникорентгенологическая диагностика поражения органов дыхания при болезни Шёгрена. Тезисы докладов IV Всесоюзного съезда ревматологов. Минск;1991:25.

7. Matsuyama N, Ashizawa K, Okimoto T, Kadota J, Amano H, Hayashi K. Pulmonary lesions associated with Sjögren’s syndrome: Radiographic and CT findings. Br J Radiol. 2003;76(912):880-884. doi: 10.1259/bjr/18937619

8. Luppi F, Sebastiani M, Sverzellati N, Cavazza A, Salvarani C, Manfredi A. Lung complications of Sjogren syndrome. Eur Respir Rev. 2020;29(157):200021. doi: 10.1183/16000617.0021-2020

9. Howling SJ, Hansell DM, Wells AU, Nicholson AG, Flint JD, Müller NL. Follicular bronchiolitis: Thin-section CT and histologic findings. Radiology. 1999;212(3):637-642. doi: 10.1148/radiology.212.3.r99se04637

10. Flament T, Bigot A, Chaigne B, Henique H, Diot E, MarchandAdam S. Pulmonary manifestations of Sjögren’s syndrome. Eur Respir Rev. 2016;25(140):110-123. doi: 10.1183/16000617.0011-2016

11. Ito I, Nagai S, Kitaichi M, Nicholson AG, Johkoh T, Noma S, et al. Pulmonary manifestations of primary Sjogren’s syndrome: A clinical, radiologic, and pathologic study. Am J Respir Crit Care Med. 2005;171(6):632-638. doi: 10.1164/rccm.200403-417OC

12. Shi JH, Liu HR, Xu WB, Feng RE, Zhang ZH, Tian XL, et al. Pulmonary manifestations of Sjögren’s syndrome. Respiration. 2009;78(4):377-386. doi: 10.1159/000214841

13. Papadimitraki ED, Kyrmizakis DE, Kritikos I, Boumpas DT. Ear-nose-throat manifestations of autoimmune rheumatic diseases. Clin Exp Rheumatol. 2004;22(4):485-494.

14. Papiris SA, Maniati M, Constantopoulos SH, Roussos C, Moutsopoulos HM, Skopouli FN. Lung involvement in primary Sjögren’s syndrome is mainly related to the small airway disease. Ann Rheum Dis. 1999;58(1):61-64. doi: 10.1136/ard.58.1.61

15. Natalini JG, Johr C, Kreider M. Pulmonary Involvement in Sjögren Syndrome. Clin Chest Med. 2019;40(3):531-544. doi: 10.1016/j.ccm.2019.05.002

16. Gupta S, Ferrada MA, Hasni SA. Pulmonary manifestations of primary Sjögren’s syndrome: Underlying immunological mechanisms, clinical presentation, and management. Front Immunol. 2019;10:1327. doi: 10.3389/fimmu.2019.01327

17. Kakugawa T, Sakamoto N, Ishimoto H, Shimizu T, Nakamura H, Nawata A, et al. Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjögren’s syndrome. Respir Med. 2018;137:95-102. doi: 10.1016/j.rmed.2018.02.023

18. Yachoui R, Leon C, Sitwala K, Kreidy M. Pulmonary MALT lymphoma in patients with Sjögren’s Syndrome. Clin Med Res. 2017;15(1-2):6-12. doi: 10.3121/cmr.2017.1341

19. Wise LM, Arkfeld DG. A patient with primary Sjogren’s syndrome, cystic lung disease, and MALT lymphoma treated successfully with rituximab: A case-based review. Clin Rheumatol. 2020;39(4):1357-1362. doi: 10.1007/s10067-019-04886-7

20. Васильев ВИ, Пробатова НА, Тупицын НН, Варламова ЕЮ, Логвиненко ОА, Ковригина АМ, и др. Лимфопролиферативные заболевания при болезни Шегрена. Онкогематология. 2007;2(3):16-26.

21. Gorodetskiy VR, Probatova NA, Vasilyev VI. Characteristics of diffuse large B-cell lymphoma in patients with primary Sjögren’s syndrome. Int J Rheum Dis. 2020;23(4):540-548. doi: 10.1111/1756-185X.13800

22. Risselada AP, Kruize AA, Goldschmeding R, Lafeber FP, Bijlsma JW, van Roon JA. The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren’s syndrome. Ann Rheum Dis. 2014;73(8):1537-1540. doi: 10.1136/annrheumdis-2013-204634

23. Carubbi F, Alunno A, Cipriani P, Bartoloni E, Baldini C, Quartuccio L, et al. A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren’s syndrome. Lupus. 2015;24(3):315-320. doi: 10.1177/0961203314554251

24. Quartuccio L, Baldini C, Priori R, Bartoloni E, Carubbi F, Alunno A, et al.; GRISS Group. Cryoglobulinemia in Sjögren syndrome: A disease subset that links higher systemic disease activity, autoimmunity, and local B cell proliferation in mucosaassociated lymphoid tissue. J Rheumatol. 2017;44(8):1179-1183. doi: 10.3899/jrheum.161465

25. Sambataro G, Ferro F, Orlandi M, Sambataro D, Torrisi SE, Quartuccio L, et al. Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sj°gren’s syndrome: A systematic review from the Italian Society of Rheumatology. Autoimmun Rev. 2020;19(2):102447. doi: 10.1016/j.autrev.2019.102447

26. Hida A, Imaizumi M, Sera N, Akahoshi M, Soda M, Maeda R, et al. Association of human T lymphotropic virus type I with Sjogren syndrome. Ann Rheum Dis. 2010;69(11):2056-2057. doi: 10.1136/ard.2010.128736

27. Crocker TF, Brown L, Lam N, Wray F, Knapp P, Forster A. Information provision for stroke survivors and their carers. Cochrane Database Syst Rev. 2021;11(11):CD001919. doi: 10.1002/14651858.CD001919.pub4

28. Yamashiro T, Kamiya H, Miyara T, Gibo S, Ogawa K, Akamine T, et al. CT scans of the chest in carriers of human T-cell lymphotropic virus type 1: Presence of interstitial pneumonia. Acad Radiol. 2012;19(8):952-957. doi: 10.1016/j.acra.2012.03.020

29. Okada F, Ando Y, Yoshitake S, Yotsumoto S, Matsumoto S, Wakisaka M, et al. Pulmonary CT findings in 320 carriers of human T-lymphotropic virus type 1. Radiology. 2006;240(2):559-564. doi: 10.1148/radiol.2402050886

30. Kadota J, Mukae H, Fujii T, Seki M, Tomono K, Kohno S. Clinical similarities and differences between human T-cell lymphotropic virus type 1-associated bronchiolitis and diffuse panbronchiolitis. Chest. 2004;125(4):1239-1247. doi: 10.1378/chest.125.4.1239

31. Nannini C, Jebakumar AJ, Crowson CS, Ryu JH, Matteson EL. Primary Sjogren’s syndrome 1976–2005 and associated interstitial lung disease: A population-based study of incidence and mortality. BMJ Open. 2013;3(11):e003569. doi: 10.1136/bmjopen-2013-003569

32. Luppi F, Sebastiani M, Silva M, Sverzellati N, Cavazza A, Salvarani C, et al. Interstitial lung disease in Sjögren’s syndrome: A clinical review. Clin Exp Rheumatol. 2020;38 Suppl 126(4):291-300.

33. Kelly C, Gardiner P, Pal B, Griffiths I. Lung function in primary Sjögren’s syndrome: A cross sectional and longitudinal study. Thorax. 1991;46(3):180-183. doi: 10.1136/thx.46.3.180

34. Manfredi A, Sebastiani M, Cerri S, Cassone G, Bellini P, Casa GD, et al. Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement. Clin Rheumatol. 2017;36(6):1261-1268. doi: 10.1007/s10067-017-3601-1

35. Roca F, Dominique S, Schmidt J, Smail A, Duhaut P, Lévesque H, et al. Interstitial lung disease in primary Sjögren’s syndrome. Autoimmun Rev. 2017;16(1):48-54. doi: 10.1016/j.autrev.2016.09.017

36. Ter Borg EJ, Kelder JC. Development of new extra-glandular manifestations or associated auto-immune diseases after establishing the diagnosis of primary Sjögren’s syndrome: A long-term study of the Antonius Nieuwegein Sjögren (ANS) cohort. Rheumatol Int. 2017;37(7):1153-1158. doi: 10.1007/s00296-017-3715-4

37. Wang Y, Hou Z, Qiu M, Ye Q. Risk factors for primary Sjögren syndrome-associated interstitial lung disease. J Thorac Dis. 2018;10(4):2108-2117. doi: 10.21037/jtd.2018.03.120

38. Enomoto Y, Takemura T, Hagiwara E, Iwasawa T, Fukuda Y, Yanagawa N, et al. Prognostic factors in interstitial lung disease associated with primary Sjögren’s syndrome: A retrospective analysis of 33 pathologically-proven cases. PLoS One. 2013;8(9):e73774. doi: 10.1371/journal.pone.0073774

39. Gao H, Zou YD, Zhang XW, He J, Zhang J, Sun Y, et al. Interstitial lung disease in non-sicca onset primary Sjögren’s syndrome: A large-scale case-control study. Int J Rheum Dis. 2018;21(7):1423-1429. doi: 10.1111/1756-185X.13334

40. Reina D, Roig Vilaseca D, Torrente-Segarra V, Cerdà D, Castellví I, Díaz Torné C, et al. Sjögren’s syndrome-associated interstitial lung disease: A multicenter study. Reumatol Clin. 2016;12(4):201-205. doi: 10.1016/j.reuma.2015.09.003

41. Cain HC, Noble PW, Matthay RA. Pulmonary manifestations of Sjögren’s syndrome. Clin Chest Med. 1998;19(4):687-viii. doi: 10.1016/s0272-5231(05)70110-6

42. García-Carrasco M, Ramos-Casals M, Rosas J, Pallarés L, CalvoAlen J, Cervera R, et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81(4):270-280. doi: 10.1097/00005792200207000-00003

43. Yazisiz V, Ozbudak IH, Nizam I, Erbasan F, Avci AB, Ozbudak O, et al. A case of primary Sjögren’s syndrome with pulmonary-limited Wegener’s granulomatosis. Rheumatol Int. 2010;30(9):1235-1238. doi: 10.1007/s00296-009-1045-x

44. Davidson BK, Kelly CA, Griffiths ID. Ten year follow up of pulmonary function in patients with primary Sjögren’s syndrome. Ann Rheum Dis. 2000;59(9):709-712. doi: 10.1136/ard.59.9.709

45. Gao H, Zhang XW, He J, Zhang J, An Y, Sun Y, et al. Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjögren syndrome patients: A casecontrol study. Medicine (Baltimore). 2018;97(24):e11003. doi: 10.1097/MD.0000000000011003

46. Li X, Xu B, Ma Y, Li X, Cheng Q, Wang X, et al. Clinical and laboratory profiles of primary Sjogren’s syndrome in a Chinese population: A retrospective analysis of 315 patients. Int J Rheum Dis. 2015;18(4):439-446. doi: 10.1111/1756-185X.12583

47. Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH. Interstitial lung disease in primary Sjögren syndrome. Chest. 2006;130(5):1489-1495. doi: 10.1378/chest.130.5.1489

48. Dong X, Zhou J, Guo X, Li Y, Xu Y, Fu Q, et al. A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren’s syndrome-related interstitial lung disease in a Chinese population. Clin Rheumatol. 2018;37(11):2981-2988. doi: 10.1007/s10067-018-4289-6

49. Zhang T, Yuan F, Xu L, Sun W, Liu L, Xue J. Characteristics of patients with primary Sjögren’s syndrome associated interstitial lung disease and relevant features of disease progression. Clin Rheumatol. 2020;39(5):1561-1568. doi: 10.1007/s10067-01904906-6

50. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, et al.; GEMESS Study Group. Primary Sjögren syndrome in Spain: Clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87(4):210-219. doi: 10.1097/MD.0b013e318181e6af

51. Lee AS, Scofield RH, Hammitt KM, Gupta N, Thomas DE, Moua T, et al.; Consensus Expert Panel (CEP) Members. Consensus guidelines for evaluation and management of pulmonary disease in Sjögren’s. Chest. 2021;159(2):683-698. doi: 10.1016/j.chest.2020.10.011

52. He C, Chen Z, Liu S, Chen H, Zhang F. Prevalence and risk factors of interstitial lung disease in patients with primary Sjögren’s syndrome: A systematic review and meta-analysis. Int J Rheum Dis. 2020;23(8):1009-1018. doi: 10.1111/1756-185X.13881

53. Sogkas G, Hirsch S, Olsson KM, Hinrichs JB, Thiele T, Seeliger T, et al. Lung involvement in primary Sjögren’s syndrome – An underdiagnosed entity. Front Med (Lausanne). 2020;7:332. doi: 10.3389/fmed.2020.00332

54. Chen MH, Chou HP, Lai CC, Chen YD, Chen MH, Lin HY, et al. Lung involvement in primary Sjögren’s syndrome: Correlation between high-resolution computed tomography score and mortality. J Chin Med Assoc. 2014;77(2):75-82. doi: 10.1016/j.jcma.2013.11.001

55. Lohrmann C, Uhl M, Warnatz K, Ghanem N, Kotter E, Schaefer O, et al. High-resolution CT imaging of the lung for patients with primary Sjogren’s syndrome. Eur J Radiol. 2004;52(2):137-143. doi: 10.1016/j.ejrad.2004.01.006

56. Franquet T, Giménez A, Monill JM, Díaz C, Geli C. Primary Sjögren’s syndrome and associated lung disease: CT findings in 50 patients. Am J Roentgenol. 1997;169(3):655-658. doi: 10.2214/ajr.169.3.9275871

57. Liebow AA, Carrington CB. Diffuse pulmonary lymphoreticular infiltrations associated with dysproteinemia. Med Clin North Am. 1973;57(3):809-843. doi: 10.1016/s0025-7125(16)32278-7

58. Ramos-Casals M, Brito-Zerón P, Seror R, Bootsma H, Bowman SJ, Dörner T, et al.; EULAR Sjögren Syndrome Task Force. Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford). 2015;54(12):2230-2238. doi: 10.1093/rheumatology/kev200

59. Honda O, Johkoh T, Ichikado K, Tomiyama N, Maeda M, Mihara N, et al. Differential diagnosis of lymphocytic interstitial pneumonia and malignant lymphoma on high-resolution CT. Am J Roentgenol. 1999;173(1):71-74. doi: 10.2214/ajr.173.1.10397102

60. Swigris JJ, Berry GJ, Raffin TA, Kuschner WG. Lymphoid interstitial pneumonia: A narrative review. Chest. 2002;122(6):2150-2164. doi: 10.1378/chest.122.6.2150

61. Johkoh T, Müller NL, Pickford HA, Hartman TE, Ichikado K, Akira M, et al. Lymphocytic interstitial pneumonia: Thin-section CT findings in 22 patients. Radiology. 1999;212(2):567-572. doi: 10.1148/radiology.212.2.r99au05567

62. Carignan S, Staples CA, Müller NL. Intrathoracic lymphoproliferative disorders in the immunocompromised patient: CT findings. Radiology. 1995;197(1):53-58. doi: 10.1148/radiology.197.1.7568853

63. Watanabe Y, Koyama S, Miwa C, Okuda S, Kanai Y, Tetsuka K, et al. Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma in Sjögren’s syndrome showing only the LIP pattern radiologically. Intern Med. 2012;51(5):491-495. doi: 10.2169/internalmedicine.51.6242

64. Rajagopala S, Singh N, Gupta K, Gupta D. Pulmonary amyloidosis in Sjogren’s syndrome: A case report and systematic review of the literature. Respirology. 2010;15(5):860-866. doi: 10.1111/j.1440-1843.2010.01772.x

65. Jeong YJ, Lee KS, Chung MP, Han J, Chung MJ, Kim KI, et al. Amyloidosis and lymphoproliferative disease in Sjögren syndrome: Thin-section computed tomography findings and histopathologic comparisons. J Comput Assist Tomogr. 2004;28(6):776-781. doi: 10.1097/00004728-200411000-00008

66. Masaki Y, Sugai S. Lymphoproliferative disorders in Sjögren’s syndrome. Autoimmun Rev. 2004;3(3):175-182. doi: 10.1016/S1568-9972(03)00102-2

67. Nicholson AG, Wotherspoon AC, Diss TC, Hansell DM, Du Bois R, Sheppard MN, et al. Reactive pulmonary lymphoid disorders. Histopathology. 1995;26(5):405-412. doi: 10.1111/j.1365-2559.1995.tb00247.x

68. Tirelli C, Zanframundo G, Valentini A, Bortolotto C, Dore R, Oggionni T, et al. CT-guided biopsy in the differential diagnosis of Sjogren syndrome associated cystic lung disease: A case of lung nodular AL-k amyloidosis. Radiol Case Rep. 2020;15(11):23312334. doi: 10.1016/j.radcr.2020.08.012

69. Heraganahally S, Digges M, Haygarth M, Liyanaarachchi K, Kalro A, Mehra S. Pulmonary AL-amyloidosis masquerading as lung malignancy in an Australian Indigenous patient with Sjogren’s syndrome. Respir Med Case Rep. 2018;26:94-97. doi: 10.1016/j.rmcr.2018.11.015

70. Федоров АБ, Кучма ЮМ. Болезнь отложения легких цепей (болезнь Randall). Клиническая онкогематология. 2009;2(4):362-366.

71. Kijner CH, Yousem SA. Systemic light chain deposition disease presenting as multiple pulmonary nodules. A case report and review of the literature. Am J Surg Pathol. 1988;12(5):405-413. doi: 10.1097/00000478-198805000-00009

72. Khoor A, Myers JL, Tazelaar HD, Kurtin PJ. Amyloid-like pulmonary nodules, including localized light-chain deposition: Clinicopathologic analysis of three cases. Am J Clin Pathol. 2004;121(2):200-204. doi: 10.1309/3GEC-PW24-02F6-V8EK

73. Colombat M, Stern M, Groussard O, Droz D, Brauner M, Valeyre D, et al. Pulmonary cystic disorder related to light chain deposition disease. Am J Respir Crit Care Med. 2006;173(7):777780. doi: 10.1164/rccm.200510-1620CR

74. Wei P, Tao R, Liu Y, Xie H, Jiang S, Yu D, et al. Pulmonary light chain deposition disease: A case series and literature review. Ann Transl Med. 2020;8(9):588. doi: 10.21037/atm-20-2708

75. Gupta N, Vassallo R, Wikenheiser-Brokamp KA, McCormack FX. Diffuse cystic lung disease. Part I. Am J Respir Crit Care Med. 2015;191(12):1354-1366. doi: 10.1164/rccm.201411-2094CI

76. Степанян ИЭ. Легочный гистиоцитоз из клеток Лангерганса: факты и гипотезы. Практическая пульмонология. 2014;(1): 30-33.

77. Gupta N, Vassallo R, Wikenheiser-Brokamp KA, McCormack FX. Diffuse cystic lung disease. Part II. Am J Respir Crit Care Med. 2015;192(1):17-29. doi: 10.1164/rccm.201411-2096CI

78. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Ann Rheum Dis. 2007;66(3):351-357. doi: 10.1136/ard.2006.057919

79. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al.; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/ European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733-748. doi: 10.1164/rccm.201308-1483ST

80. Deheinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho JV, Saldiva PH, de Carvalho CR. Interstitial lung disease in primary Sjögren’s syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med. 1996;154(3 Pt 1):794799. doi: 10.1164/ajrccm.154.3.8810621

81. Cha SI, Fessler MB, Cool CD, Schwarz MI, Brown KK. Lymphoid interstitial pneumonia: Clinical features, associations and prognosis. Eur Respir J. 2006;28(2):364-369. doi: 10.1183/09031936.06.00076705

82. Lantuejoul S, Moulai N, Quetant S, Brichon PY, Brambilla C, Brambilla E, et al. Unusual cystic presentation of pulmonary nodular amyloidosis associated with MALT-type lymphoma. Eur Respir J. 2007;30(3):589-592. doi: 10.1183/09031936.00136605

83. Lim JK, Lacy MQ, Kurtin PJ, Kyle RA, Gertz MA. Pulmonary marginal zone lymphoma of MALT type as a cause of localised pulmonary amyloidosis. J Clin Pathol. 2001;54(8):642-646. doi: 10.1136/jcp.54.8.642

84. Wieker K, Röcken C, Koenigsmann M, Roessner A, Franke A. Pulmonary low-grade MALT-lymphoma associated with localized pulmonary amyloidosis. A case report. Amyloid. 2002;9(3):190-193. doi: 10.3109/13506120209114821

85. Ikeda SI, Hineno A, Yoshinaga T, Matsuo K, Suga T, Shiina T, et al. Sjögren syndrome-related plasma cell disorder and multifocal nodular AL amyloidosis: Clinical picture and pathological findings. Amyloid. 2019;26(4):225-233. doi: 10.1080/13506129.2019.1660636

86. Васильев ВИ, Логвиненко ОА, Пробатова НА, Пальшина СГ, Шорникова НС, Ананьева ЛП, и др. Роль биопсии околоушной слюнной железы в ранней диагностике лимфом при болезни Шегрена. Терапевтический архив. 2009;(6):20-27.

87. Gorodetskiy VR, Probatova NA, Radenska-Lopovok SG, Ryzhikova NV, Sidorova YV, Sudarikov AB. Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren’s syndrome patients: Case series study and review of the literature. Rheumatol Int. 2020;40(3):499-506. doi: 10.1007/s00296-019-04470-x

88. Hansen LA, Prakash UB, Colby TV. Pulmonary lymphoma in Sjögren’s syndrome. Mayo Clin Proc. 1989;64(8):920-931. doi: 10.1016/s0025-6196(12)61219-1

89. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren’s syndrome: A cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65(6):796-803. doi: 10.1136/ard.2005.041186

90. Enomoto Y, Takemura T, Hagiwara E, Iwasawa T, Okudela K, Yanagawa N, et al. Features of usual interstitial pneumonia in patients with primary Sjögren’s syndrome compared with idiopathic pulmonary fibrosis. Respir Investig. 2014;52(4): 227-235. doi: 10.1016/j.resinv.2014.02.003

91. Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG. Topical and systemic medications for the treatment of primary Sjögren’s syndrome. Nat Rev Rheumatol. 2012;8(7): 399-411. doi: 10.1038/nrrheum.2012.53

92. Justet A, Ottaviani S, Dieudé P, Taillé C. Tocilizumab for refractory organising pneumonia associated with Sjögren’s disease. BMJ Case Rep. 2015;2015:bcr2014209076. doi: 10.1136/bcr-2014-209076

93. Ankita G, Shashi D. Pulmonary lymphomatoid granulomatosis – A case report with review of literature. Indian J Surg Oncol. 2016;7(4):484-487. doi: 10.1007/s13193-016-0525-1

94. Weisbrot IM. Lymphomatoid granulomatosis of the lung, associated with a long history of benign lymphoepithelial lesions of the salivary glands and lymphoid interstitial pneumonitis. Report of a case. Am J Clin Pathol. 1976;66(5):792-801. doi: 10.1093/ajcp/66.5.792

95. Волков АВ. Легочная артериальная гипертензия при системных заболеваниях соединительной ткани. Научнопрактическая ревматология. 2015;53(1):69-77. doi: 10.14412/19954484-2015-69-77

96. Launay D, Hachulla E, Hatron PY, Jais X, Simonneau G, Humbert M. Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: Report of 9 new cases and review of the literature. Medicine (Baltimore). 2007;86(5):299-315. doi: 10.1097/MD.0b013e3181579781

97. Liu Z, Yang X, Tian Z, Qian J, Wang Q, Zhao J, et al. The prognosis of pulmonary arterial hypertension associated with primary Sjögren’s syndrome: A cohort study. Lupus. 2018;27(7):1072-1080. doi: 10.1177/0961203318756287

98. Wang J, Li M, Wang Q, Zhang X, Qian J, Zhao J, et al. Pulmonary arterial hypertension associated with primary Sjögren’s syndrome: A multicentre cohort study from China. Eur Respir J. 2020;56(5):1902157. doi: 10.1183/13993003.02157-2019

99. Langenskiöld E, Bonetti A, Fitting JW, Heinzer R, Dudler J, Spertini F, et al. Shrinking lung syndrome successfully treated with rituximab and cyclophosphamide. Respiration. 2012;84(2):144-149. doi: 10.1159/000334947

100. Carmier D, Diot E, Diot P. Shrinking lung syndrome: recognition, pathophysiology and therapeutic strategy. Expert Rev Respir Med. 2011;5(1):33-39. doi: 10.1586/ers.10.84

101. Трофимов ЕА, Лейнеман ЯА, Мазуров ВИ, Файзенберг РМ, Голимбиевская ТА. Особенности поражения легких у пациентов с системной красной волчанкой. Вестник СевероЗападного государственного медицинского университета им. И.И. Мечникова. 2014;6(1):20-29.

102. Reddy KS, Jha V, Nada R, Kohli HS, Sud K, Gupta KL, et al. Respiratory paralysis in Sjogren syndrome with normal renal function. Na tl Med J India. 2003;16(5):253-234.

103. Ohtani H, Imai H, Kodama T, Hamai K, Komatsuda A, Wakui H, et al. Severe hypokalaemia and respiratory arrest due to renal tubular acidosis in a patient with Sjögren syndrome. Nephrol Dial Transplant. 1999;14(9):2201-2203. doi: 10.1093/ndt/14.9.2201

104. Poux JM, Peyronnet P, Le Meur Y, Favereau JP, Charmes JP, Leroux-Robert C. Hypokalemic quadriplegia and respiratory arrest revealing primary Sjögren’s syndrome. Clin Nephrol. 1992;37(4):189-191.

105. Vitali C, Palombi G, Baldini C, Benucci M, Bombardieri S, Covelli M, et al. Sjögren’s Syndrome Disease Damage Index and disease activity index: Scoring systems for the assessment of disease damage and disease activity in Sjögren’s syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum. 2007;56(7):2223-2231. doi: 10.1002/art.22658

106. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al.; EULAR Sjögren’s Task Force. EULAR Sjogren’s syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010;69(6):1103-1109. doi: 10.1136/ard.2009.110619

107. Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 2017;69(8):1670-1678. doi: 10.1002/art.40130

108. Shi L, Fu Q, Chen N, Liu R, Zheng Y. Angiopoietin-like protein 2 as a novel marker for patients with primary Sjogren’s syndrome-related interstitial lung disease. Clin Exp Med. 2020;20(3):393-399. doi: 10.1007/s10238-020-00623-6

109. Kamiya Y, Fujisawa T, Kono M, Nakamura H, Yokomura K, Koshimizu N, et al. Prognostic factors for primary Sjögren’s syndrome-associated interstitial lung diseases. Respir Med. 2019;159:105811. doi: 10.1016/j.rmed.2019.105811

110. Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, De Vita S, Dörner T, et al.; EULAR-Sjögren Syndrome Task Force Group. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3-18. doi: 10.1136/annrheumdis-2019-216114

111. Oldham JM, Lee C, Valenzi E, Witt LJ, Adegunsoye A, Hsu S, et al. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med. 2016;121:117-122. doi: 10.1016/j.rmed.2016.11.007

112. Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN. Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst Rev. 2018;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2

113. Zhang L, Mo H, Zhu M, Wang L. Effect of cyclophosphamide on cytokines in patients with primary Sjögren’s syndrome-associated interstitial lung disease in South China. Rheumatol Int. 2013;33(6): 1403-1407. doi: 10.1007/s00296-012-2561-7

114. Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640-646. doi: 10.3899/jrheum.121043

115. Koo SM, Kim SY, Choi SM, Lee HK; Korean Interstitial Lung Diseases Study Group. Korean guidelines for diagnosis and management of interstitial lung diseases: Part 5. Connective tissue disease associated interstitial lung disease. Tuberc Respir Dis (Seoul). 2019;82(4):285-297. doi: 10.4046/trd.2019.0009

116. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968-1977. doi: 10.1056/NEJMoa1113354

117. Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sjögren syndrome. Nat Rev Rheumatol. 2016;12(8):456-471. doi: 10.1038/nrrheum.2016.100

118. Amlani B, Elsayed G, Barvalia U, Kanne JP, Meyer KC, Sandbo N, et al. Treatment of primary Sjögren’s syndromerelated interstitial lung disease: A retrospective cohort study. Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(2):136-147. doi: 10.36141/svdld.v37i2.8461

119. Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O, et al.; Club Rhumatismes et Inflammations and the French Society of Rheumatology. Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: Results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis. 2013;72(6):1026-1031. doi: 10.1136/annrheumdis-2012-202293

120. Chen MH, Chen CK, Chou HP, Chen MH, Tsai CY, Chang DM. Rituximab therapy in primary Sjögren’s syndrome with interstitial lung disease: A retrospective cohort study. Clin Exp Rheumatol. 2016;34(6):1077-1084.

121. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, et al. Treatment of primary Sjögren syndrome with rituximab: A randomized trial. Ann Intern Med. 2014;160(4):233-242. doi: 10.7326/M13-1085

122. Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, et al.; INBUILD trial investigators. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8(5):453-460. doi: 10.1016/S22132600(20)30036-9

123. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al.; INBUILD Trial Investigators. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718-1727. doi: 10.1056/NEJMoa1908681

124. Enomoto Y, Nakamura Y, Colby TV, Inui N, Suda T. Pirfenidone for primary Sjögren’s syndrome-related fibrotic interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(1):91-96. doi: 10.36141/svdld.v34i1.5091

125. Vacchi C, Sebastiani M, Cassone G, Cerri S, Della Casa G, Salvarani C, et al. Therapeutic options for the treatment of interstitial lung disease related to connective tissue diseases. A narrative review. J Clin Med. 2020;9(2):407. doi: 10.3390/jcm9020407

126. Uffmann M, Kiener HP, Bankier AA, Baldt MM, Zontsich T, Herold CJ. Lung manifestation in asymptomatic patients with primary Sjögren syndrome: Assessment with high reso lution CT and pulmonary function tests. J Thorac Imaging. 2001;16(4):282-289. doi: 10.1097/00005382-200110000-00009

127. Romão VC, Talarico R, Scirè CA, Vieira A, Alexander T, Baldini C, et al. Sjögren’s syndrome: State of the art on clinical practice guidelines. RMD Open. 2018;4(Suppl 1):e000789. doi: 10.1136/rmdopen-2018-000789